



(51) International Patent Classification:
A61K 31/506 (2006.01) *A61K 31/16* (2006.01)

(21) International Application Number:
PCT/US2011/058610

(22) International Filing Date:
31 October 2011 (31.10.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/409,080 1 November 2010 (01.11.2010) US
61/411,829 9 November 2010 (09.11.2010) US
61/412,330 10 November 2010 (10.11.2010) US
61/534,323 13 September 2011 (13.09.2011) US

(71) Applicant (for all designated States except US): **AVILA THERAPEUTICS, INC.** [US/US]; 45 Wiggins Avenue, Bedford, MA 01730 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LEE, Kwangho** [US/US]; 22 Middlesex Circle, #7, Waltham, MA 02452 (US). **NIU, Deqiang** [US/US]; 30 Grapevine Avenue, Lexington, MA 02421 (US). **PETTER, Russell, C.** [US/US]; 22 Robinwood Lane, Stow, MA 01775 (US). **BAEVSKY, Matthew, Frank** [US/US]; 65 West Street, Northborough, MA 01532 (US). **SINGH, Juswinder** [GB/US]; 94 Heritage Avenue, Ashland, MA 01721 (US).

(74) Agents: **BUTEAU, Kristen, C.** et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: HETEROCYCLIC COMPOUNDS AND USES THEREOF

(57) Abstract: Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) kinase activity are disclosed. Selectivity in inhibition of various mutant-EGFR is disclosed. Pharmaceutical compositions containing the pyrimidine derivatives, and methods of treating diseases associated with EGFR kinase activity comprising administration of the pyrimidine derivatives or pharmaceutical compositions containing the pyrimidine derivative, are described.

